Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Indapamide for progressive multiple sclerosis
NL-OMON61339Phase 2Not yet recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of indapamide in primary progressive multiple sclerosis (PPMS) and secondary-progressive multiple sclerosis (SPMS), sponsored by Amsterdam University Medical Center. Primary endpoint: Worsening in timed 25-foot walk at 12 months. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
indapamide
03
Conditions
primary progressive multiple sclerosis (PPMS)secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on NL-OMON61339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61339.